WINNIPEG, MANITOBA -- (MARKET WIRE) -- May 07, 2007 -- Medicure Inc. (TSX: MPH)(AMEX: MCU), a cardiovascular focused biopharmaceutical company, announced today that following a meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its Phase 3 MEND-CABG II trial.
